Sermonix Pharmaceuticals Announces Breast Cancer Research Publication of Paper Examining Lasofoxifene’s Preclinical Effects on Aromatase Inhibitor Resistant Non-ESR1 Mutated Breast Cancer
June 10, 2024 10:17 ET
|
Sermonix Pharmaceuticals Inc.
In preclinical mouse models, results suggested lasofoxifene could be an effective therapy for all hormone treatment-resistant breast tumorsPhase 3 ELAINE-3 study is currently investigating...
Sermonix Pharmaceuticals Announces Chinese Approval of Investigational New Drug Application for Lasofoxifene
June 06, 2024 09:00 ET
|
Sermonix Pharmaceuticals Inc.
IND approval in China allows Shanghai Henlius Biotech, Sermonix’s Chinese development partner for oral lasofoxifene, to enroll ELAINE-3 trial patients in ChinaUnder strategic collaboration agreement...
Sermonix Pharmaceuticals to Present Poster on ELAINE-3 Trial in Progress at ASCO 2024
May 30, 2024 09:21 ET
|
Sermonix Pharmaceuticals Inc.
COLUMBUS, Ohio, May 30, 2024 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast...
Sermonix Pharmaceuticals Announces ‘Menopause’ Journal Publication of Article on Oral Lasofoxifene’s Effects on Vaginal Atrophy in Postmenopausal Women
April 29, 2024 09:00 ET
|
Sermonix Pharmaceuticals Inc.
COLUMBUS, Ohio, April 29, 2024 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic...
Sermonix to Host KOL Fireside Chat on Advancements in the Metastatic Breast Cancer Treatment Landscape on April 22, 2024
April 19, 2024 16:26 ET
|
Sermonix Pharmaceuticals Inc.
COLUMBUS, Ohio, April 19, 2024 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic...
Sermonix Pharmaceuticals Announces MBC Alliance Membership, New ‘Discover ELAINE’ Website
February 12, 2024 09:00 ET
|
Sermonix Pharmaceuticals Inc.
COLUMBUS, Ohio, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast...
Henlius and Sermonix Announce Strategic Collaboration and Exclusive License Agreements for Novel Endocrine Therapy Lasofoxifene
January 10, 2024 19:30 ET
|
Sermonix Pharmaceuticals Inc.
Partnership expands Henlius’ portfolio with license of exclusive China rights to develop, manufacture and commercialize lasofoxifene; Sermonix retains all other global rightsHenlius to facilitate...
Sermonix Pharmaceuticals Shares Results of Third Survey on ESR1 and Metastatic Breast Cancer Patient Quality of Life
December 12, 2023 09:00 ET
|
Sermonix Pharmaceuticals Inc.
Most patients minimized or hid side effects from their health care providers for fear of negative perceptions, reduced treatment efficacy, or being taken off a drug or out of a clinical trialSexual...
Sermonix Pharmaceuticals Shares Pharmacokinetic and Baseline Genomic Clinical Data Tied to ELAINE Lasofoxifene Trials of Patients With ESR1 Mutations
December 12, 2023 09:00 ET
|
Sermonix Pharmaceuticals Inc.
COLUMBUS, Ohio, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast...
Sermonix Pharmaceuticals Announces Publication of ELAINE-1 and ELAINE-2 Trial Results in Annals of Oncology
December 11, 2023 09:00 ET
|
Sermonix Pharmaceuticals Inc.
COLUMBUS, Ohio, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast...